Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-18
DOI
10.1186/s13045-021-01090-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- (2021) Tiziano Barbui et al. LEUKEMIA
- COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
- (2021) Joyce K. Hwang et al. Journal of Hematology & Oncology
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
- (2021) Patrick Harrington et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID-19 vaccines for patients with haematological conditions
- (2021) Clare Sun et al. Lancet Haematology
- Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid‐19 Pandemic. A Campus ALL Study
- (2020) Robin Foà et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively.
- (2020) Fabrizio Bonelli et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
- (2020) Massimo Breccia et al. LEUKEMIA
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- (2020) Francesco Passamonti et al. Lancet Haematology
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
- (2020) Heinz Ludwig et al. LEUKEMIA
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
- (2020) Sara Galimberti et al. Frontiers in Oncology
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
- (2019) Corrado Girmenia et al. BLOOD REVIEWS
- Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
- (2019) Malgorzata Mikulska et al. LANCET INFECTIOUS DISEASES
- Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
- (2019) Kristine A. Frerichs et al. HAEMATOLOGICA
- Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
- (2019) Alemnew F Dagnew et al. LANCET INFECTIOUS DISEASES
- Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
- (2018) C T Rieger et al. ANNALS OF ONCOLOGY
- Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
- (2017) Federica Costa et al. Oncotarget
- Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma
- (2015) M. Hahn et al. HAEMATOLOGICA
- Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma
- (2015) M. Hahn et al. HAEMATOLOGICA
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
- (2010) H. de Lavallade et al. HAEMATOLOGICA
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started